Every year roughly 5,000 people are diagnosed with Amyotrophic Lateral Sclerosis (ALS, which is why ALS in the Heartland ...

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn ...

In a powerful act of compassion and community, Starr’s Mill High School organized an early graduation for rising senior ...

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

Detailed price information for Klotho Neurosciences Inc (KLTO-Q) from The Globe and Mail including charting and trades.

In 2023, Chantler took it upon himself to look for a specialized mobility device called a 'TrailRider' to rent for an outdoor ...

Brain-machine interfaces (BMIs) are becoming lifelines for people facing severe motor impairments. For many individuals with ...

JJ Potrikus, vice president of the New York Collegiate Baseball League, joined Bridge Street for details this morning along ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Neurizon Therapeutics has announced it has received positive feedback from the US Food and Drug Administration (FDA) on its ...